(Reuters) -India’s Glenmark Pharmaceuticals reported a 72% jump in second-quarter adjusted profit on Friday, on recovery in key North American and European markets.

The drugmaker reported a consolidated net profit of 6.1 billion rupees ($69.4 million) for the quarter ended September 30, up from 3.54 billion rupees a year ago.

Total revenue from operations rose 76% to 60.47 billion rupees during the quarter.

For further earnings highlights, click here.

KEY CONTEXT

Its secondary sales growth from India formulation business grew 10.8%, while net sales from Glenmark’s core businesses in North America and Europe rose 7.4% and 8.5%, respectively.

The Indian pharmaceutical market grew 7.3% in value in September, driven by strong sales in cardiovascular, anti-diabetic, and anti-infectives th

See Full Page